...Yes. Good morning, Tejas. Thank you very much for having us here. We appreciate it. Yes. So cancer testing market for what we do, we think is in the $6 billion to $8 billion range, and it's growing at the rate of about 6% to 8%, mainly because of demographics, but there's a lot happening beneath that, and it's a very interesting market because it's really a revolutionary time in oncology care. It's because of all these advances in medicine and technology and science. We're starting to understand a lot more about cancer. So where we fit in, in the industry, is that there are very large companies that do oncology testing along with us. Those large companies are companies like Quest Diagnostics and LabCorp and Mayo and others. And those companies have very, very broad menus to do, a lot of other things in addition to oncology. And then there are some specialty players, typically operate with only 1 technology or in 1 disease state, and then we have NeoGenomics that's right in the middle. So...
